SGLT2 inhibitors, which were initially indicated as antidiabetic drugs, have recently gained significant attention in clinical trials and preclinical studies for their therapeutic potential in cardiovascular and neurodegenerative diseases [16,32,33,34]. The gene discussed is SLC5A2; the disease is neurodegenerative disease.